<DOC>
	<DOCNO>NCT00666484</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . It yet know regimen combination chemotherapy effective Hodgkin lymphoma . PURPOSE : This phase II trial study side effect three different regimen combination chemotherapy see well work treat young patient Hodgkin lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Younger Patients With Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish neurotoxicity OEPA+COPP chemotherapy young adult . Secondary - To determine response rate patient treated regimen . - To determine disease-free survival patient treat regimen . - To determine overall survival patient treat regimen . - To determine gonadal toxicity patient treated regimen . OUTLINE : Patients assign treatment group accord stage . - Group 1 ( patient stage 1A , 1B , 2A disease ) : Patients receive OEPA chemotherapy comprise vincristine IV day 1 , 8 , 15 ; oral prednisolone day 1-15 ; etoposide IV day 1-5 ; doxorubicin hydrochloride IV day 1 15 . Courses repeat every 28 day 2 course . Patients achieve partial response also undergo radiotherapy completion chemotherapy ; patient achieve complete response undergo radiotherapy . - Group 2 ( patient stage 2AE , 2B , 3A disease ) : Patients receive 2 course OEPA chemotherapy group 1 . Patients receive COPP chemotherapy comprise cyclophosphamide IV day 1 8 ; vincristine IV day 1 8 ; oral procarbazine hydrochloride day 1-15 ; oral prednisolone day 1-15 . Courses repeat every 28 day 2 course . Patients also undergo radiotherapy completion chemotherapy . - Group 3 ( patient stage 2BE , 3AE , 3BE , 3B , 4A , 4B disease ) : Patients receive 2 course OEPA chemotherapy group 1 . Patients receive COPP chemotherapy group 2 . Treatment COPP chemotherapy repeat every 28 day 4 course . Patients also undergo radiotherapy completion chemotherapy . In group , treatment continue absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven denovo classical Hodgkin lymphoma Any stage disease No nodular lymphocytepredominant Hodgkin lymphoma PATIENT CHARACTERISTICS : No know suspect HIV infection No preexist neurological disorder No serious comorbidity may prevent administration study treatment No previous malignancy Not pregnant nursing Fertile patient must use effective contraception 1 year completion study treatment Creatinine ≤ 1.5 time upper limit normal ( ULN ) unless due lymphoma ALT/AST ≤ 1.5 time ULN unless due lymphoma Bilirubin ≤ 2 time ULN unless due lymphoma PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy No prior organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
</DOC>